Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
ALX ONCOLOGY HOLDINGS INC (ALXO) Stock Price & Overview
NASDAQ:ALXO • US00166B1052
Current stock price
1.7 USD
+0.12 (+7.59%)
At close:
1.72 USD
+0.02 (+1.18%)
After Hours:
The current stock price of ALXO is 1.7 USD. Today ALXO is up by 7.59%. In the past month the price decreased by -14.14%. In the past year, price increased by 219.01%.
ALXO Key Statistics
52-Week Range0.404 - 2.66
Current ALXO stock price positioned within its 52-week range.
1-Month Range1.51 - 2.045
Current ALXO stock price positioned within its 1-month range.
- Market Cap
- 223.737M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.79
- Dividend Yield
- N/A
ALXO Stock Performance
Today
+7.59%
1 Week
+6.92%
1 Month
-14.14%
3 Months
-2.30%
Longer-term
6 Months +10.39%
1 Year +219.01%
2 Years -90.01%
3 Years -71.38%
5 Years -97.29%
10 Years N/A
ALXO Stock Chart
ALXO Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ALXO. When comparing the yearly performance of all stocks, ALXO is one of the better performing stocks in the market, outperforming 96.39% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
ALXO Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ALXO. ALXO may be in some trouble as it scores bad on both profitability and health.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ALXO Earnings
Next Earnings DateMay 7, 2026
Last Earnings DateFeb 27, 2026
PeriodQ4 / 2025
EPS Reported-$0.37
Revenue Reported
EPS Surprise -0.07%
Revenue Surprise %
ALXO Forecast & Estimates
13 analysts have analysed ALXO and the average price target is 4.69 USD. This implies a price increase of 176% is expected in the next year compared to the current price of 1.7.
Analysts
Analysts81.54
Price Target4.69 (175.88%)
EPS Next Y56.31%
Revenue Next YearN/A
ALXO Financial Highlights
Over the last trailing twelve months ALXO reported a non-GAAP Earnings per Share(EPS) of -1.79. The EPS increased by 31.15% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-101.69M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -172.23% | ||
| ROE | -391.42% | ||
| Debt/Equity | 0.2 |
Chartmill High Growth Momentum
EPS Q2Q%32.73%
Sales Q2Q%N/A
EPS 1Y (TTM)31.15%
Revenue 1Y (TTM)N/A
ALXO Ownership
Ownership
Inst Owners30.4%
Shares131.61M
Float117.17M
Ins Owners0.59%
Short Float %1.75%
Short Ratio2.13
ALXO Industry Overview
ALXO operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
27%
Outperformed 27% of sub-industries
3 Month Rank
47%
Outperformed 47% of sub-industries
6 Month Rank
30%
Outperformed 30% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 4.1%
- New Lows
- 4.6%
- Average ROE
- 48.3%
- Average Profit Margin
- 20.7%
- Average Operating Margin
- 33.6%
- Average P/E
- 26.4
- Average Fwd P/E
- 22.3
- Average Debt/Equity
- 2.2
ALXO Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.88 | 360.632B | ||
| AMGN | AMGEN INC | 15.16 | 182.426B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 159.919B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.94 | 107.655B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.82 | 72.562B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.34 | 40.188B | ||
| INSM | INSMED INC | N/A | 29.146B | ||
| BIIB | BIOGEN INC | 11.58 | 28.527B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.853B | ||
| NTRA | NATERA INC | N/A | 27.602B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.55 | 25.03B | ||
| INCY | INCYTE CORP | 10.43 | 19.722B | ||
| MRNA | MODERNA INC | N/A | 18.132B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ALXO
Company Profile
ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. The company is headquartered in South San Francisco, California and currently employs 43 full-time employees. The company went IPO on 2020-07-17. The firm's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. The company is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.
Company Info
IPO: 2020-07-17
ALX ONCOLOGY HOLDINGS INC
323 Allerton Avenue
South San Francisco CALIFORNIA 94010 US
CEO: Jaume Pons
Employees: 43
Phone: 13026587581
ALX ONCOLOGY HOLDINGS INC / ALXO FAQ
What does ALXO do?
ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. The company is headquartered in South San Francisco, California and currently employs 43 full-time employees. The company went IPO on 2020-07-17. The firm's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. The company is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.
Can you provide the latest stock price for ALX ONCOLOGY HOLDINGS INC?
The current stock price of ALXO is 1.7 USD. The price increased by 7.59% in the last trading session.
What is the dividend status of ALX ONCOLOGY HOLDINGS INC?
ALXO does not pay a dividend.
How is the ChartMill rating for ALX ONCOLOGY HOLDINGS INC?
ALXO has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the sector and industry classification for ALX ONCOLOGY HOLDINGS INC?
ALX ONCOLOGY HOLDINGS INC (ALXO) operates in the Health Care sector and the Biotechnology industry.
When does ALX ONCOLOGY HOLDINGS INC (ALXO) report earnings?
ALX ONCOLOGY HOLDINGS INC (ALXO) will report earnings on 2026-05-07.